Proton pump inhibitors and the risk of inflammatory bowel disease: cause, protopathic bias or others?

Competing Interests: Competing interests: BDY has received research grants from Celltrion and Pfizer Korea; consulting fees from AbbVie Korea, BMS Pharmaceutical Korea, Celltrion, Chong Kun Dang Pharm, CJ Red BIO, Curacle, Daewoong Pharm, Ferring Korea, IQVIA, Janssen Korea, Kangstem Biotech, Korea Otsuka Pharm, Korea United Pharm, Medtronic Korea, NanoEntek, ORGANOIDSCIENCES, Pfizer Korea, Samsung Bioepis, Takeda and Takeda Korea; and speaking fees from AbbVie Korea, Celltrion, Cornerstones Health, Curacle, Ferring Korea, IQVIA, Janssen Korea, Pfizer Korea and Takeda Korea. None of these disclosures are directly associated with this study.